Patents Examined by Maria Marvich
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11453712
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 27, 2022
    Assignee: Lentigen Technology Inc.
    Inventors: Rimas Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Method for reestablishment of pluripotent stem cells
    Patent number: 11441125
    Abstract: The present application relates to a method for reestablishing stem cells capable of forming chimeras, and cells obtained by the method. The method of the present invention is a technique for monocloning stem cells, for example, capable of forming chimeras from a heterogeneous cell population to obtain high-quality stem cells.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: September 13, 2022
    Assignee: JICHI MEDICAL UNIVERSITY
    Inventors: Hitoshi Endo, Yasumitsu Nagao, Yutaka Hanazono, Kaoru Tominaga, Tsukasa Ohmori
  • Composition for treating pain
    Patent number: 11433145
    Abstract: The present invention relates to: a composition for alleviating or treating pain, the composition comprising glutamate decarboxylase and a gene coding for an anti-inflammatory cytokine; and a method for alleviating or treating pain by using the composition.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 6, 2022
    Assignee: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong Kim, Heonsik Choi, Kyoungbaek Choi, Minjung Kim, Hyeonyoul Lee, Minju Kim, Daewook Kim, Min Kim, Jangjoon Park
  • Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
    Patent number: 11419950
    Abstract: The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 23, 2022
    Assignee: Vrije Universiteit Brussel
    Inventors: Thierry Vandendriessche, Marinee Chuah
  • Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
    Patent number: 11419926
    Abstract: In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: August 23, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Hiroaki Uchida, Justus B. Cohen
  • Modified soluble VEGF receptor-1 genes and vectors for gene therapy
    Patent number: 11414678
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 16, 2022
    Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Richard J. Samulski
  • Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
    Patent number: 11414657
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In certain embodiments, such modified oligonucleotides provide improved properties of scrRNA.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 16, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Meghdad Rahdar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett
  • Changing eye color by gene transduction
    Patent number: 11400039
    Abstract: A person's iris color can lighten, such as from brown to lighter brown, green, hazel, or blue, by introducing a melanocyte-killing agent through the cornea of the person's eye and contacting the anterior surface of the iris with the agent at a dose sufficient to kill melanocytes in the iris stroma.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 2, 2022
    Inventor: James W. Hill
  • System for the biocontrol of disease-transmitting mosquitoes and their eggs using horizontally transferable symbiotic bacteria to deliver pathogen specific interfering RNA polynucleotides
    Patent number: 11396653
    Abstract: The inventive technology relates to novel paratransgenic strategies for the control of pathogens. The inventive technology may specifically include a novel paratransgenic system configured to deliver one or more inhibitory RNA molecules to pathogen/disease-transmitting organisms. In a preferred embodiment, the invention may include one or more genetically engineered symbiotic bacteria configured to persist throughout the life-cycle of a mosquito and deliver one or more interfering RNA molecules to pathogen/disease-transmitting mosquitoes.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: July 26, 2022
    Assignees: PEBBLE LABS INC., COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Richard Sayre, Jiannong Xu, Bradley R. Borlee, Konstantinos Lymperopoulos, Rebekah Kading, William Black, Kenneth Olson, Carol Blair
  • Microfluidic device for analyzing gene expression
    Patent number: 11396012
    Abstract: A microfluidic device is disclosed which comprises: (i) at least one reaction unit having a test chamber connected to at least one microchannel, wherein a surface of at least a portion of said reaction unit is attached to an isolated nucleic acid; and (ii) a flow-through channel having at least one inlet port and at least one outlet port, said flow-through channel and said microchannel being of dimensions to allow reactant diffusion to and from said reaction unit, wherein the diffusion time of said reactant along the microchannel is shorter than the flow time along the microchannel.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 26, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Roy Bar-Ziv, Eyal Karzbrun, Alexandra Tayar
  • Methods of obtaining tumor-specific T cell receptors
    Patent number: 11390659
    Abstract: Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 19, 2022
    Assignees: SYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.
    Inventors: Xiangjun Zhou, Yanyan Han, Xiaoling Liang, Xihe Chen
  • Methods for reversing multiple resistance in animal cells
    Patent number: 11369650
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: June 28, 2022
    Inventor: Per Sonne Holm
  • Recombinant virus replicon systems and uses thereof
    Patent number: 11364310
    Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecules of interest. The disclosure relates to nucleic acid constructs, such as expression vectors, containing a modified replicon RNA which includes a modified 5?-unstranslated region (5?-UTR) and, optionally, at least some of its original viral sequence encoding structural proteins having been deleted. Also disclosed are methods for producing polypeptides of interest.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 21, 2022
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventor: Kurt Iver Kamrud
  • Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
    Patent number: 11357868
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: June 14, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
    Patent number: 11357867
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: June 14, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Genetically engineered vaccinia viruses
    Patent number: 11344589
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: May 31, 2022
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
  • Transgenic microalgae and use thereof for oral delivery of proteins
    Patent number: 11344590
    Abstract: Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: May 31, 2022
    Assignee: TRANSALGAE ISRAEL LTD.
    Inventors: Shiri Moshitzky, Doron Eisenstadt, Guy Levi, Ofra Chen
  • Aligned fiber and method of use thereof
    Patent number: 11318227
    Abstract: A scaffold comprising an aligned fiber. Further, a scaffold comprising one or more electrospun fibers wherein a fast Fourier transform (FFT) analysis result of the fibers have adjacent major peaks with about 180° apart from each other. Also, methods for promoting differentiation of stem cells into osteoblasts, chondrocytes, ligament or tendon, the method comprising culturing the cells on the scaffold or aligned fiber in conditions suitable for the cell differentiation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: May 3, 2022
    Inventors: Michael Francis, Roy Ogle
  • ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases
    Patent number: 11312943
    Abstract: The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 26, 2022
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Johannes Backs, Zegeye Jebessa, Lorenz Lehmann, Hugo Katus, Oliver Müller
  • Methods of preparing cancer treatments and methods of treating cancer
    Patent number: 11278606
    Abstract: Methods for preparing antigen-loaded dendritic cells (DCs) for treatment of cancer in a subject are provided, using an electroporation apparatus having an electroporation chamber including an upper electrode, a lower electrode and a path defined in the electroporation chamber. The electroporation apparatus includes a first input allowing passage of DCs into the electroporation chamber and a first output allowing passage of antigen-loaded DCs from the electroporation chamber. The first input and the first output are separated by an offset distance. Methods of treating cancer by administering antigen-loaded DCs are also provided.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 22, 2022
    Assignees: NANT HOLDINGSIP, LLC, NANOCAV, LLC
    Inventors: Patrick Soon-Shiong, Chihwei Chang